Day One Biopharmaceuticals, Inc. (DAWN)
- Previous Close
13.50 - Open
13.50 - Bid 13.86 x 200
- Ask 17.52 x 100
- Day's Range
13.35 - 13.91 - 52 Week Range
9.67 - 18.07 - Volume
1,001,546 - Avg. Volume
982,330 - Market Cap (intraday)
1.366B - Beta (5Y Monthly) -1.52
- PE Ratio (TTM)
-- - EPS (TTM)
-1.94 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
39.25
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.
dayonebio.comRecent News: DAWN
View MoreResearch Reports: DAWN
View MorePerformance Overview: DAWN
Trailing total returns as of 9/4/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: DAWN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: DAWN
View MoreValuation Measures
Market Cap
1.33B
Enterprise Value
965.54M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
142.49
Price/Book (mrq)
4.33
Enterprise Value/Revenue
117.86
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-42.22%
Return on Equity (ttm)
-45.71%
Revenue (ttm)
8.19M
Net Income Avi to Common (ttm)
-167.48M
Diluted EPS (ttm)
-1.94
Balance Sheet and Cash Flow
Total Cash (mrq)
361.87M
Total Debt/Equity (mrq)
0.06%
Levered Free Cash Flow (ttm)
-98.02M